<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Vionnet J</dc:creator>
  <dc:creator>Sempoux C</dc:creator>
  <dc:creator>Pascual M</dc:creator>
  <dc:creator>Sánchez-Fueyo A</dc:creator>
  <dc:creator>Colmenero J</dc:creator>
  <dc:date>2020</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Despite unique immunoregulatory properties pointing toward tolerance, the liver allograft can be negatively impacted by humoral alloreactivity, with immediate as well as long-term harmful consequences. With regard to the unmet need of long-term outcomes improvement after liver transplantation, donor-specific antibodies have recently been the matter of intense study in this context. We review here recent advances regarding the understanding of the impact of preformed as well as de novo anti-human leukocyte antigen donor-specific antibodies in liver transplantation and discuss potential strategies to overcome this problem.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/44690</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.gastrohep.2019.09.010</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31810796</dc:relation>
  <dc:source>Gastroenterologia y hepatologia. - 2020</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">AED</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Alloreactivity</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Alorreactividad</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Antibody-mediated rejection</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">DSA</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Ensayo en fase sólida</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Immune tolerance</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Inmunotolerancia</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Liver transplantation</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Rechazo mediado por anticuerpos</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Solid-phase assay</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Trasplante de hígado</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Allografts</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Antibodies</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Graft Rejection</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">HLA Antigens</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Immunosuppression</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Liver Transplantation</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Tissue Donors</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Transplantation Immunology</dc:subject>
  <dc:title xmlns:ns22="xml" ns22:lang="en">Donor-specific antibodies in liver transplantation.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>